Best of ASCO - 2014 Annual Meeting



Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Contributing factors of early breast cancer mortality reduction by molecular subtypes from 2000 to 2014: A single institute experience.

Adjuvant Therapy

Breast Cancer—Local/Regional/Adjuvant

2018 ASCO Annual Meeting

Abstract No:

J Clin Oncol 36, 2018 (suppl; abstr e12506)

Author(s): Shin-Cheh Chen, Hsiu-Pei Tsai, Hsien-Kun Chang, Yung-Chang Lin, Shih Che Shen, Wen-Lin Kuo, Chi-Chang Yu, Hsu-Huan Chou, Chia-Hui Chu, Yi-Ting Huang, Shir-Hwa Ueng; Chang Gung Memorial Hospital, Taoyuan, Taiwan; Chang Gung Memorial Hospita, Taoyuan, Taiwan; Chang Gung Memorial Hosp, Taipei, Taiwan; Division of Breast Surgery, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Abstract Disclosures


Background: To clarify whether the Asia-Pacific breast cancer patients get small decline mortality in comparison to American white, we compared the survival differences between 2 decades(2000-2014) of T1-2N0 breast cancer by molecular subtypes and analysis the contributing factors. Methods: A total of 4478 patients with T1-2N0 breast cancer who received curative breast surgery at Chang Gung Memorial Hospital, Linkou, and divided into two period cohorts according to their surgical date (earlier cohort 2000 - 2008, n = 2397; recent cohort 2009-2014, n = 2081). The trends of clinicopathologic characteristics, treatment strategies and outcome between two cohorts were reviewed retrospectively. Mortality reduction was compared between the ER/HER2 subtypes. The effect of treatment factors on disease free survival (DFS), distant metastasis free survival (DMFS) and overall survival (OS) were determined using a stepwise Cox regression model. Results: The median follow up duration was 73 months. There was a trend of older mean age, smaller tumor size, more patients received conserving surgery and more ER (+) patients (71%) in recent cohort was found. The HER2(+) subtype was the poorest of 7-year DFS,DMFS and OS (p< 0.0001)in comparison to others. The 7-year DFS were 90.9%, 85.2%,84.1% and 81.0% in luminal A,luminal B, triple negative and HER2(+) subtypes, 7-year OS were 97.1%, 94.4%, 90.8% and 91.5% in those subtypes, respectively. The differences of survival data in earlier and recent cohort by the four subtypes are summarized in the table. In HER2(+) subtype, targeted therapy was the only contributing factor for survival benefit both in DFS and OS, and no significant specific treatment factor found in other subtypes. Conclusions: The estimated survival improvement was largest in HER2(+) subtype and targeted therapy was the only contributing factor.

5-year DFS
5-year DMFS
5-year OS
Luminal A92.494.90.02196.397.7N.S98.498.5N.S
Luminal B86.490.5N.S92.698.20.02396.799.1N.S
Triple negative85.888.8N.S90.696.00.03792.393.0N.S

Other Abstracts in this Sub-Category:


1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.

Meeting: 2018 ASCO Annual Meeting Abstract No: LBA1 First Author: Joseph A. Sparano
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy


2. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial.

Meeting: 2018 ASCO Annual Meeting Abstract No: 500 First Author: Michael Gnant
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy


3. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study.

Meeting: 2018 ASCO Annual Meeting Abstract No: 501 First Author: Robert E. Coleman
Category: Breast Cancer—Local/Regional/Adjuvant - Adjuvant Therapy